What is HC Wainwright’s Estimate for MOLN FY2026 Earnings?

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) – HC Wainwright lifted their FY2026 earnings estimates for Molecular Partners in a note issued to investors on Monday, November 2nd. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($1.67) for the year, up from their prior estimate of ($1.81). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Molecular Partners’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Molecular Partners’ Q4 2026 earnings at ($0.44) EPS, Q1 2027 earnings at ($0.45) EPS, Q2 2027 earnings at ($0.39) EPS, Q3 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.35) EPS and FY2027 earnings at ($1.51) EPS.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a research note on Friday, October 2nd. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $8.38.

Molecular Partners Stock Performance

Shares of Molecular Partners stock opened at $3.19 on Wednesday. Molecular Partners has a 1 year low of $3.09 and a 1 year high of $5.36. The company has a market capitalization of $128.77 million, a P/E ratio of -1.90 and a beta of 1.17. The company’s fifty day moving average is $3.99 and its two-hundred day moving average is $4.17.

Molecular Partners (NASDAQ:MOLN) last released its quarterly earnings results on Thursday, October 29th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.08.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland. The company develops therapeutic molecules based on its proprietary DARPin platform, which uses designed ankyrin repeat proteins to create targeted, multi-specific medicines intended to address complex disease pathways.

Molecular Partners’ research and development activities have focused primarily on oncology, ophthalmology and infectious diseases. Its pipeline has included experimental programs designed to engage multiple biological targets, with the goal of improving treatment effectiveness and addressing limitations associated with conventional antibody-based therapies.